# Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

> **NCT00423189** · PHASE4 · TERMINATED · sponsor: **David M. Brown, M.D.** · enrollment: 7 (actual)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab (Lucentis)
- **DRUG:** 0.5mg ranibizumab

## Key facts

- **NCT ID:** NCT00423189
- **Lead sponsor:** David M. Brown, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2016-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00423189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00423189, "Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00423189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*